Due Diligence Webinar – Antisense Therapeutics (ASX: ANP)

By Staff Writers | More Articles by Staff Writers

 

In a first time exclusive hear from Managing Director & CEO – Mark Diamond, Chair – Charmaine Gittleson & Non-Executive Director – Gill Price. Antisense Therapeutics (ASX: ANP) is an Australian publicly-listed biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases.

RELATED COMPANIESTagged